The Congenital Ichthyosis drugs in development market research report provides comprehensive information on the therapeutics under development for Congenital Ichthyosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Congenital Ichthyosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Congenital Ichthyosis and features dormant and discontinued products.
GlobalData tracks 12 drugs in development for Congenital Ichthyosis by ten companies/universities/institutes. The top development phase for Congenital Ichthyosis is preclinical with five drugs in that stage. The Congenital Ichthyosis pipeline has 11 drugs in development by companies and one by universities/ institutes. Some of the companies in the Congenital Ichthyosis pipeline products market are: DermaXon, Azitra and Krystal Biotech.
The key targets in the Congenital Ichthyosis pipeline products market include Cytochrome P450 26A1 (hP450RAI or Cytochrome P450RAI or Retinoic Acid 4 Hydroxylase or Cytochrome P450 Retinoic Acid Inactivating 1 or Retinoic Acid Metabolizing Cytochrome or CYP26A1 or EC 1.14.), Cytochrome P450 26B1 (Cytochrome P450 26A2 or Cytochrome P450 Retinoic Acid Inactivating 2 or Retinoic Acid Metabolizing Cytochrome or CYP26B1 or EC 1.14.), and Filaggrin (FLG).
The key mechanisms of action in the Congenital Ichthyosis pipeline product include Cytochrome P450 26A1 (hP450RAI or Cytochrome P450RAI or Retinoic Acid 4 Hydroxylase or Cytochrome P450 Retinoic Acid Inactivating 1 or Retinoic Acid Metabolizing Cytochrome or CYP26A1 or EC 1.14.) Inhibitor with two drugs in Preclinical. The Congenital Ichthyosis pipeline products include four routes of administration with the top ROA being Topical and five key molecule types in the Congenital Ichthyosis pipeline products market including Small Molecule, and Gene Therapy.
Congenital Ichthyosis overview
Congenital ichthyosis is a collective name for a group of monogenetic disorders of cornification, sometimes associated with systemic symptoms. There may be an abnormal quality or quantity of scale produced, abnormal thickness of stratum corneum or abnormal keratinocyte kinetics, often associated with skin inflammation. HI is inherited in an autosomal recessive fashion and arises secondary to mutations in the ABCA12 gene 1–3.
For a complete picture of Congenital Ichthyosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
